曲妥珠单抗

Trastuzumab is used to treat HER2-positive breast cancer.
它被用来治疗HER2阳性乳腺癌。
The doctor prescribed trastuzumab as part of the patient's chemotherapy regimen.
医生把这个药作为病人化疗方案的一部分开给了她。
Trastuzumab binds to HER2 receptors on cancer cells, inhibiting their growth.
它能与癌细胞上的HER2受体结合，阻止其生长。
A phase III clinical trial showed that trastuzumab significantly improved survival rates in HER2-positive patients.
一项III期临床试验结果显示，对于HER2阳性患者，曲妥珠单抗显著提高了生存率。
After receiving trastuzumab, the patient experienced a reduction in tumor size.
接受曲妥珠单抗治疗后，病人的肿瘤尺寸有所缩小。
Trastuzumab is often combined with other targeted therapies for more effective treatment.
它常与其他靶向疗法联合使用以增强疗效。
Manufacturers of trastuzumab have developed different dosing schedules to optimize patient compliance.
生产者为优化患者的依从性，设计了多种给药方案。
The side effects of trastuzumab can include fatigue and immune system reactions.
副作用可能包括疲劳和免疫系统反应。
Trastuzumab was approved by the FDA for the prevention of Her2-positive metastatic breast cancer.
美国食品药品监督管理局批准了它用于预防HER2阳性转移性乳腺癌。
Patients on trastuzumab therapy should regularly undergo monitoring for potential side effects.
接受曲妥珠单抗治疗的患者应定期监测可能出现的副作用。